Biomea Fusion to present Phase 1 results for oral GLP-1 drug BMF-650 at ObesityWeek 2026
BMEA•Biomea Fusion will present Phase 1 results for its investigational oral GLP-1 drug BMF-650 at ObesityWeek on Nov. 16, 2026, in National Harbor, Maryland.
1. Presentation scheduled
Biomea Fusion will present results from the first-in-human study of BMF-650, an investigational oral small-molecule GLP-1 receptor agonist in its diabetes and obesity pipeline, at ObesityWeek on Nov. 16, 2026, in National Harbor, Maryland.
